Comparison among plasma-derived clotting Factor VIII by using
Author(s)
Timperio, Anna Maria
Gevi, Federica
Grazzini, Giuliano
Vaglio, Stefania
Zolla, Lello
Date Issued
2010
Type
Article
Abstract
Background. Deficiency or dysfunction of coagulation factor VIII (FVIII) is the underlying
cause of haemophilia A. Haemophilic patients are at present treated with plasma-derived FVIII
(pdFVIII) or recombinant FVIII (rFVIII) in order to correct their clotting deficiency. pdFVIII
concentrates are exclusively produced from human plasma upon pooling from multiple donors.
It is not know whether the presence of excess of other plasma proteins, in addition to von
Willebrand factor, could stimulate untoward immune responses in the recipient. Thus, information
regarding the presence of contaminants in commercial products is of concern.
Materials and Methods. Two commercially available pdFVIII concentrates were
characterized through SDS-PAGE and mass spectrometry Emoclot® and Beriate®
.
Results. The components of two pdFVIII products considered in this study were well
identified by mass spectrometry analysis, in both cases we found abundant components coming
from blood plasma, and some other contaminants. Only in Beriate®
we also found truncated
form of pdFVIII.
Conclusion. The two pdFVIII examined showed the presence of vWF, Fibrinogen in excess,
and other substances that could be considered as contaminants or impurities.
Additional information
L'articolo è disponibile sul sito dell'editore http://www.bloodtransfusion.it
Citation
Timperio, A. M. et al. 2010. Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry. "Blood Transfusion" 8(suppl. 3): s98-s104
File(s)![Thumbnail Image]()
Name
timperio et al.pdf
Size
11.85 MB
Format
Adobe PDF
Checksum (MD5)
cff816165317798c5714dfaa8bfc8f3e